ATXS
Price
$6.25
Change
-$0.09 (-1.42%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
352.15M
25 days until earnings call
OVID
Price
$0.47
Change
+$0.08 (+20.51%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
34.08M
32 days until earnings call
Interact to see
Advertisement

ATXS vs OVID

Header iconATXS vs OVID Comparison
Open Charts ATXS vs OVIDBanner chart's image
Astria Therapeutics
Price$6.25
Change-$0.09 (-1.42%)
Volume$3.91K
Capitalization352.15M
Ovid Therapeutics
Price$0.47
Change+$0.08 (+20.51%)
Volume$5.14K
Capitalization34.08M
ATXS vs OVID Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. OVID commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and OVID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (ATXS: $6.33 vs. OVID: $0.48)
Brand notoriety: ATXS and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 28% vs. OVID: 1457%
Market capitalization -- ATXS: $352.15M vs. OVID: $34.08M
ATXS [@Biotechnology] is valued at $352.15M. OVID’s [@Biotechnology] market capitalization is $34.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and OVID are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 6 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 4 bearish.
  • OVID’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, OVID is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а -6.50% price change this week, while OVID (@Biotechnology) price change was +14.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

OVID is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($352M) has a higher market cap than OVID($34.1M). ATXS YTD gains are higher at: -29.195 vs. OVID (-48.667). OVID has higher annual earnings (EBITDA): -56.4M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. OVID (43M). ATXS has less debt than OVID: ATXS (5.06M) vs OVID (14.4M). OVID has higher revenues than ATXS: OVID (548K) vs ATXS (0).
ATXSOVIDATXS / OVID
Capitalization352M34.1M1,032%
EBITDA-124.4M-56.4M221%
Gain YTD-29.195-48.66760%
P/E RatioN/AN/A-
Revenue0548K-
Total Cash295M43M686%
Total Debt5.06M14.4M35%
FUNDAMENTALS RATINGS
ATXS vs OVID: Fundamental Ratings
ATXS
OVID
OUTLOOK RATING
1..100
2211
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4751
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (29) in the Pharmaceuticals Major industry is in the same range as ATXS (57) in the Biotechnology industry. This means that OVID’s stock grew similarly to ATXS’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to ATXS’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as ATXS (97) in the Biotechnology industry. This means that OVID’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (47) in the Biotechnology industry is in the same range as OVID (51) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew similarly to OVID’s over the last 12 months.

OVID's P/E Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSOVID
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 9 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRT5.780.42
+7.84%
Trio-Tech International
APD293.584.59
+1.59%
Air Products & Chemicals
NXE6.93-0.01
-0.14%
NexGen Energy Ltd
SLN6.22-0.13
-2.05%
Silence Therapeutics Plc
TUYA2.49-0.06
-2.35%
Tuya